Caffeine
- Generic Name
- Caffeine
- Brand Names
- Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10N4O2
- CAS Number
- 58-08-2
- Unique Ingredient Identifier
- 3G6A5W338E
- Background
Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, whic...
- Indication
Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broa...
- Associated Conditions
- Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
- Associated Therapies
- Analgesia, Antacid therapy, Athletic Performance
To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02629354
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Bloemfontein, South Africa
Caffeine in Amblyopia Study
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT02594358
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
A Study to Determine if Caffeine Accelerates Emergence From Anesthesia
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 8
- Registration Number
- NCT02567968
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Early Versus Late Caffeine for ELBW Newborns
- Conditions
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 110
- Registration Number
- NCT02524249
- Locations
- 🇺🇸
Hutzel Women's Hospital, Detroit, Michigan, United States
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT02520752
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Emory University School of Medicine/Winship Cancer Institute SC-2, Atlanta, Georgia, United States
Evaluating the Role of Expectations in Response to Caffeine Consumption: An RCT
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 205
- Registration Number
- NCT02461693
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02397382
Dabigatran in an Interaction Probe Drug Cocktail
- Conditions
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT02361619
- Locations
- 🇫🇮
Teutori CPRU, Turku, Finland
Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Spaulding Rehabilitation Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT02323698
- Locations
- 🇺🇸
Spaulding Rehabilitation Hospital, Cambridge, Massachusetts, United States
Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 26
- Registration Number
- NCT02311088
- Locations
- 🇸🇪
Dept of Cardiology, Östra hospital, Gothenburg, Sweden
🇸🇪Dept of Cardiology, Gävle Hospital, Gävle, Sweden
🇸🇪Dept of Cardiology, Skåne University Hospital, Lund, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.